Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | M Mita, A Mita, B Chmielowski, M Postow, E Hamilton, S Pant, Roger Waltzman, Eric Rowinsky, Michael Szarek, Foster Gonsalves, Isabel Kurth, Celia Andreu, Ilana Pollack, Daniel Mucida, Raissa Tanqueco, Sohail Tavazoie and Masoud Tavazoie | ||||||||||||
Title | A phase 1 trial of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies | ||||||||||||
|
|||||||||||||
URL | http://mct.aacrjournals.org/content/17/1_Supplement/B001 | ||||||||||||
Abstract Text | Mol Cancer Ther 2018;17(1 Suppl):Abstract nr B001 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
RGX-104 | RGX104|RGX 104 | RGX-104 activates liver-X nuclear hormone receptor (LXR), resulting in ApoE expression and enhancement of antitumor immunity (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr B001, PMID: 32448508). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|